| Progressive Orthotic & Prosthetic S | |
| 1531 W 32nd St, Ste 201, Joplin, Missouri 64804 | |
| (417) 621-0055 |
| Name | Progressive Orthotic & Prosthetic S |
|---|---|
| Organization Name | Progressive Orthotic & Prosthetic Services, Inc. |
| Location | 1531 W 32nd St, Ste 201, Joplin, Missouri 64804 |
| Type | Prosthetic/Orthotic Supplier |
| Phone | (417) 621-0055 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.
Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
› Verified 6 days ago
| NPI Number | 1740258953 |
| Organization Name | PROGRESSIVE ORTHOTIC & PROSTHETIC SERVICES, INC. |
| Type | Prosthetic/Orthotic Supplier |
| Address | 1531 W 32nd St, Ste 201, Joplin, MO 64804 |
| Phone Number | 417-621-0055 |
News Archive
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.
Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
› Verified 6 days ago
News Archive
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.
Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced interim six-month results from a symposium during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
› Verified 6 days ago
Adapthealth - Missouri Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7931 E 32nd St, Joplin, Missouri 64804 Phone: (844) 740-4093 | |
Advanced Orthotics And Prosthetics Type: Prosthetic/Orthotic Supplier Location: 2530s Maiden Ln, Joplin, Missouri 64804 Phone: (417) 627-0999 | |
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2024s Maiden Ln 1, Joplin, Missouri 64804 Phone: (417) 782-6212 | |
Brothers Bezold & Associates Type: Medicare Supplier Location: 2013 S Joplin Ave, Joplin, Missouri 64804 Phone: (417) 624-5005 | |
Health Essentials Type: DME Supplier - Parenteral & Enteral Nutrition Location: 1130 E 32nd St, Joplin, Missouri 64804 Phone: (417) 623-0166 |